TCR2 Therapeutics

$8.09 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About TCR2 Therapeutics

TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.

Stock Analysis

last close $8.09
1-mo return -50.4%
3-mo return -43.7%
avg daily vol. 890.17T
52-week high 35.86
52-week low 7.62
market cap. $303M
forward pe -
annual div. -
roe -35.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 97.5%
baraka

Subscribe now for daily local and international financial news

Subscribe